Imunon, Inc. (IMNN) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 78.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -219.54%, forward earnings yield 1.27%.
Criteria proven by this page:
Overall SharesGrow Score: 61/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.4 | 0.02 | 1.33 | 17.91 | - |
| 2017 | -1.2 | 0.02 | 0.93 | 49.47 | - |
| 2018 | -2.4 | 0.03 | 1.37 | 57.02 | - |
| 2019 | -2.5 | -0.18 | 2.95 | 85.87 | - |
| 2020 | -1.2 | 0.09 | 1.40 | 52.19 | - |
| 2021 | -0.2 | 0.00 | 0.06 | 6.74 | - |
| 2022 | -0.3 | 0.00 | 0.38 | 22.18 | - |
| 2023 | -0.4 | 0.01 | 0.53 | 0.00 | - |
| 2024 | -0.7 | 0.03 | 2.96 | 0.00 | - |
| 2025 | -0.6 | 0.01 | 1.15 | 0.00 | 0.13% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-178.42 | $500K | $-22.05M | -4410.7% |
| 2017 | $-40.12 | $500K | $-20.4M | -4080.4% |
| 2018 | $-10.14 | $500K | $-11.88M | -2376.7% |
| 2019 | $-11.58 | $500K | $-16.85M | -3370.3% |
| 2020 | $-10.08 | $500K | $-21.48M | -4296.7% |
| 2021 | $-3.60 | $500K | $-20.77M | -4153.9% |
| 2022 | $-5.03 | $500K | $-35.9M | -7179.6% |
| 2023 | $-10.25 | $0.00 | $-19.51M | - |
| 2024 | $-1.72 | $0.00 | $-18.62M | - |
| 2025 | $-6.83 | $0.00 | $-14.5M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.50 | $-3.27 – $-2.11 | $3.93M | $3.93M – $3.93M | 2 |
| 2027 | $-1.68 | $-1.75 – $-1.61 | $5.43M | $5.43M – $5.43M | 2 |
| 2028 | $-1.64 | $-2.01 – $-1.21 | $11.53M | $11.53M – $11.53M | 3 |
| 2029 | $-0.79 | $-0.79 – $-0.79 | $66.13M | $66.13M – $66.13M | 1 |
| 2030 | $0.04 | $0.04 – $0.04 | $172.32M | $172.32M – $172.32M | 1 |
